{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:39:38Z","timestamp":1762522778287,"version":"3.37.3"},"reference-count":108,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education (AICTE), India","doi-asserted-by":"publisher","award":["9-47\/1DC\/MODROB\/Policy-1\/2019-20"],"award-info":[{"award-number":["9-47\/1DC\/MODROB\/Policy-1\/2019-20"]}],"id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology (DST), New Delhi","doi-asserted-by":"publisher","award":["DST\/INSPIRE Fellowship\/[IF180471]"],"award-info":[{"award-number":["DST\/INSPIRE Fellowship\/[IF180471]"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>More than 150 million people have significant fungal diseases that greatly impact health care and economic expenditures. The expansion of systemic fungal infections and invasive mycoses is being driven by an increase in the number of immunocompromised patients and the recent COVID-19 patients, especially severely ill. There have been numerous cases of fungal infections linked to COVID-19, with pulmonary aspergillosis dominating at first but with the subsequent ap-pearance of mucormycosis, candidiasis, and endemic mycoses. Candida spp. is the most frequent pathogen, with approximately 1 billion infections yearly, among other species causing the most prevalent invasive fungal infections. The importance of recognizing the epidemiological shifts of invasive fungal infections in patient care cannot be overstated. Despite the enormous antifungal therapies available, these infections are difficult to diagnose and cause high morbidity and mortality rates. Treatment choices for systemic fungal infections are severely limited due to the limitations of conventional therapy effectiveness and drug toxicities. So the researchers are still looking for novel therapeutic options, such as carrier-based approaches that are convenient and cost-effective with high and long-lasting fungal infection cure rates with reduced toxicities. The focus of this study is on summarizing the nanotechnology, immunotherapy methods and the drugs under clinical trials that have been employed in treatment as carrier-based antifungal formulations. Most of these have been reported to be promising strategies with broad-spectrum antifungal action and the potential to overcome antibiotic resistance mechanisms. We speculate that this review summarized the current knowledge to its best that will help the future developments of new antifungal therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450124666221128122836","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T05:53:42Z","timestamp":1669701222000},"page":"171-190","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nascent Nanoformulations as an Insight into the Limitations of the\nConventional Systemic Antifungal Therapies"],"prefix":"10.2174","volume":"24","author":[{"given":"Subheet Kumar","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India"},{"name":"Centre for Basic and Translational Research in Health Sciences, Guru Nanak Dev University, Amritsar, 143005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjot","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya","family":"Shivgotra","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitish","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shagun","family":"Saini","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Thakur","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"Bongomin F.","year":"2017","unstructured":"Bongomin F.; Gago S.; Oladele R.; Denning D.; Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi 2017,3(4),57","journal-title":"J Fungi"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-6515-1_5","author":"Seyedmousavi S.","year":"2017","unstructured":"Seyedmousavi S.; Rafati H.; Ilkit M.; Tolooe A.; Hedayati M.T.; Verweij P.;  Systemic antifungal agents: current status and projected future developments Human fungal pathogen identification 2017,107-139","journal-title":"Systemic antifungal agents: current status and projected future developments Human fungal pathogen identification"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/antibiotics9080445","volume":"9","author":"Wall G.","year":"2020","unstructured":"Wall G.; Lopez-Ribot J.L.; Current antimycotics, new prospects, and future approaches to antifungal therapy. Antibiotics 2020,9(8),445","journal-title":"Antibiotics"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1017\/S0022215121000992","volume":"135","author":"Sharma S.","year":"2021","unstructured":"Sharma S.; Grover M.; Bhargava S.; Samdani S.; Kataria T.; Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021,135(5),442-447","journal-title":"J Laryngol Otol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"103915","DOI":"10.1016\/j.resmic.2021.103915","volume":"173","author":"Mendon&#xE7;a A.","year":"2022","unstructured":"Mendon&#xE7;a A.; Santos H.; Franco-Duarte R.; Sampaio P.; Fungal infections diagnosis - Past, present and future. Res Microbiol 2022,173(3),103915","journal-title":"Res Microbiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijantimicag.2019.01.002","volume":"53","author":"Jeong W.","year":"2019","unstructured":"Jeong W.; Keighley C.; Wolfe R.; Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. Int J Antimicrob Agents 2019,53(5),589-597","journal-title":"Int J Antimicrob Agents"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1592\/phco.23.14.1441.31938","volume":"23","author":"Wong-Beringer A.","year":"2003","unstructured":"Wong-Beringer A.; Kriengkauykiat J.; Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 2003,23(11),1441-1462","journal-title":"Pharmacotherapy"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TCRM.S40160","volume":"10","author":"Yapar N.","year":"2014","unstructured":"Yapar N.; Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014,10,95-105","journal-title":"Ther Clin Risk Manag"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"42: 219-87","DOI":"10.1016\/bs.mim.2015.05.002","author":"Pfaller M.A.","year":"2015","unstructured":"Pfaller M.A.;  Invasive fungal infections and approaches to their diagnosis Methods Microbiol 2015,42: 219-87","journal-title":"Invasive fungal infections and approaches to their diagnosis Methods Microbiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fmicb.2017.00336","volume":"8","author":"Souza A.C.O.","year":"2017","unstructured":"Souza A.C.O.; Amaral A.C.; Antifungal therapy for systemic mycosis and the nanobiotechnology era: improving efficacy, biodistribution and toxicity. Front Microbiol 2017,8,336","journal-title":"Front Microbiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijpharm.2017.03.019","volume":"523","author":"Soliman G.M.","year":"2017","unstructured":"Soliman G.M.; Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. Int J Pharm 2017,523(1),15-32","journal-title":"Int J Pharm"},{"key":"ref=12","first-page":"1","volume":"5","author":"Chandana T.","year":"2014","unstructured":"Chandana T.; Saritha ChP.S.; Comparison of safety and efficacy of luliconazole and other antifungal agents. Int J Pharm Sci Res 2014,5(1),1-9","journal-title":"Int J Pharm Sci Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/lsm.23180","volume":"52","author":"Leanse L.G.","year":"2020","unstructured":"Leanse L.G.; Goh X.S.; Dai T.; Quinine improves the fungicidal effects of antimicrobial blue light: implications for the treatment of cutaneous candidiasis. Lasers Surg Med 2020,52(6),569-575","journal-title":"Lasers Surg Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.biopha.2018.12.009","volume":"110","author":"Nami S.","year":"2019","unstructured":"Nami S.; Aghebati-Maleki A.; Morovati H.; Aghebati-Maleki L.; Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases. Biomed Pharmacother 2019,110,857-868","journal-title":"Biomed Pharmacother"},{"key":"ref=15","first-page":"2: 22-7","author":"Urban K","year":"2021","unstructured":"Urban K; Chu S; Scheufele C; The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the Global Burden of Disease Study 2017. JAAD international 2021,2: 22-7"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/1523-1747.ep12478053","volume":"66","author":"Ray T.L.","year":"1976","unstructured":"Ray T.L.; Wuepper K.D.; Experimental cutaneous candidiasis in rodents. J Invest Dermatol 1976,66(1),29-33","journal-title":"J Invest Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1128\/JB.183.18.5385-5394.2001","volume":"183","author":"Chandra J.","year":"2001","unstructured":"Chandra J.; Kuhn D.M.; Mukherjee P.K.; Hoyer L.L.; McCormick T.; Ghannoum M.A.; Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001,183(18),5385-5394","journal-title":"J Bacteriol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1099\/jmm.0.46548-0","volume":"55","author":"Enoch D.A.","year":"2006","unstructured":"Enoch D.A.; Ludlam H.A.; Brown N.M.; Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006,55(7),809-818","journal-title":"J Med Microbiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"Wisplinghoff H.","year":"2004","unstructured":"Wisplinghoff H.; Bischoff T.; Tallent S.M.; Seifert H.; Wenzel R.P.; Edmond M.B.; Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004,39(3),309-317","journal-title":"Clin Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1086\/500405","volume":"42","author":"Chu J.H.","year":"2006","unstructured":"Chu J.H.; Feudtner C.; Heydon K.; Walsh T.J.; Zaoutis T.E.; Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006,42(6),822-825","journal-title":"Clin Infect Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1086\/339202","volume":"34","author":"Marr K.A.","year":"2002","unstructured":"Marr K.A.; Carter R.A.; Crippa F.; Wald A.; Corey L.; Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002,34(7),909-917","journal-title":"Clin Infect Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/322606","volume":"33","author":"McNeil M.M.","year":"2001","unstructured":"McNeil M.M.; Nash S.L.; Hajjeh R.A.; Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001,33(5),641-647","journal-title":"Clin Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"Marr K.A.","year":"2002","unstructured":"Marr K.A.; Carter R.A.; Boeckh M.; Martin P.; Corey L.; Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002,100(13),4358-4366","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/S1473-3099(17)30443-7","volume":"17","author":"Benedict K.","year":"2017","unstructured":"Benedict K.; Richardson M.; Vallabhaneni S.; Jackson B.R.; Chiller T.; Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks. Lancet Infect Dis 2017,17(12),e403-e411","journal-title":"Lancet Infect Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/j.1469-0691.2010.03288.x","volume":"16","author":"Steinbach W.J.","year":"2010","unstructured":"Steinbach W.J.; Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010,16(9),1321-1327","journal-title":"Clin Microbiol Infect"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1128\/AAC.01504-09","volume":"54","author":"Ben-Ami R.","year":"2010","unstructured":"Ben-Ami R.; Lewis R.E.; Leventakos K.; Latg&#xE9; J.P.; Kontoyiannis D.P.; Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother 2010,54(5),1848-1854","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1086\/591861","volume":"29","author":"Hidron A.I.","year":"2008","unstructured":"Hidron A.I.; Edwards J.R.; Patel J.; NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006-2007. Infect Control Hosp Epidemiol 2008,29(11),996-1011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/499811","volume":"42","author":"Segal B.H.","year":"2006","unstructured":"Segal B.H.; Kwon-Chung J.; Walsh T.J.; Immunotherapy for fungal infections. Clin Infect Dis 2006,42(4),507-515","journal-title":"Clin Infect Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1086\/520192","volume":"29","author":"Edmond M.B.","year":"1999","unstructured":"Edmond M.B.; Wallace S.E.; McClish D.K.; Pfaller M.A.; Jones R.N.; Wenzel R.P.; Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999,29(2),239-244","journal-title":"Clin Infect Dis"},{"key":"ref=30","first-page":"255-76","author":"Chayakulkeeree M","year":"2008","unstructured":"Chayakulkeeree M; Perfect JR; Cryptococcosis. Diagnosis and treatment of human mycoses. 2008,255-76"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jhin.2006.02.014","volume":"63","author":"Vonberg R.P.","year":"2006","unstructured":"Vonberg R.P.; Gastmeier P.; Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006,63(3),246-254","journal-title":"J Hosp Infect"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ccm.2009.02.009","volume":"30","author":"Naggie S.","year":"2009","unstructured":"Naggie S.; Perfect J.R.; Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med [vii-viii.2009,30(2),337-353","journal-title":"Clin Chest Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1469-0691.2008.01978.x","volume":"14","author":"Richardson M.","year":"2008","unstructured":"Richardson M.; Lass-Fl&#xF6;rl C.; Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008,14(S4),5-24","journal-title":"Clin Microbiol Infect"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","volume":"17","author":"Groll A.H.","year":"2003","unstructured":"Groll A.H.; Gea-Banacloche J.C.; Glasmacher A.; Just-Nuebling G.; Maschmeyer G.; Walsh T.J.; Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003,17(1),159-191","journal-title":"Infect Dis Clin North Am"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","volume":"26","author":"Laniado-Labor&#xED;n R.","year":"2009","unstructured":"Laniado-Labor&#xED;n R.; Cabrales-Vargas M.N.; Amphotericin B: side effects and toxicity. Rev Iberoam Micol 2009,26(4),223-227","journal-title":"Rev Iberoam Micol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/46.2.171","volume":"46","author":"Vermes A.","year":"2000","unstructured":"Vermes A.; Guchelaar H.J.; Dankert J.; Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000,46(2),171-179","journal-title":"J Antimicrob Chemother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","volume":"30","author":"Nett J.E.","year":"2016","unstructured":"Nett J.E.; Andes D.R.; Antifungal Agents. Infect Dis Clin North Am 2016,30(1),51-83","journal-title":"Infect Dis Clin North Am"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1128\/AAC.43.8.1955","volume":"43","author":"Novelli V.","year":"1999","unstructured":"Novelli V.; Holzel H.; Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999,43(8),1955-1960","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1439-0507.2009.01805.x","volume":"54","author":"Falci D.R.","year":"2011","unstructured":"Falci D.R.; dos Santos R.P.; Wirth F.; Goldani L.Z.; Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment. Mycoses 2011,54(2),91-98","journal-title":"Mycoses"},{"key":"ref=40","first-page":"43","volume":"4","author":"Lat A.","year":"2011","unstructured":"Lat A.; Thompson G.R.; Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011,4,43-53","journal-title":"Infect Drug Resist"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/cid\/civ571","volume":"61","author":"Miceli M.H.","year":"2015","unstructured":"Miceli M.H.; Kauffman C.A.; Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015,61(10),1558-1565","journal-title":"Clin Infect Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1039\/C3NP70070D","volume":"31","author":"Balkovec J.M.","year":"2014","unstructured":"Balkovec J.M.; Hughes D.L.; Masurekar P.S.; Sable C.A.; Schwartz R.E.; Singh S.B.; Discovery and development of first in class antifungal caspofungin (CANCIDAS&#xAE;)-A case study. Nat Prod Rep 2014,31(1),15-34","journal-title":"Nat Prod Rep"},{"key":"ref=43","first-page":"7: CMPed-S8028","author":"Wilke MH","year":"2013","unstructured":"Wilke MH;  Invasive fungal infections in infants-focus on Anidulafungin Clin med insights Pediatr 2013,7: CMPed-S8028","journal-title":"Invasive fungal infections in infants-focus on Anidulafungin Clin med insights Pediatr"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","volume":"18","author":"Denning D.W.","year":"2010","unstructured":"Denning D.W.; Hope W.W.; Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010,18(5),195-204","journal-title":"Trends Microbiol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1369-5274(98)80087-8","volume":"1","author":"Georgopapadakou N.H.","year":"1998","unstructured":"Georgopapadakou N.H.; Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998,1(5),547-557","journal-title":"Curr Opin Microbiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"Herbrecht R.","year":"2002","unstructured":"Herbrecht R.; Denning D.W.; Patterson T.F.; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002,347(6),408-415","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"Walsh T.J.","year":"2008","unstructured":"Walsh T.J.; Anaissie E.J.; Denning D.W.; Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of america. Clin Infect Dis 2008,46(3),327-360","journal-title":"Clin Infect Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1513\/pats.200906-048AL","volume":"7","author":"Arnold T.M.","year":"2010","unstructured":"Arnold T.M.; Dotson E.; Sarosi G.A.; Hage C.A.; Traditional and emerging antifungal therapies. Proc Am Thorac Soc 2010,7(3),222-228","journal-title":"Proc Am Thorac Soc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","volume":"11","author":"Odds F.C.","year":"2003","unstructured":"Odds F.C.; Brown A.J.P.; Gow N.A.R.; Antifungal agents: mechanisms of action. Trends Microbiol 2003,11(6),272-279","journal-title":"Trends Microbiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5694\/j.1326-5377.2007.tb01313.x","volume":"187","author":"Chen S.C.A.","year":"2007","unstructured":"Chen S.C.A.; Sorrell T.C.; Antifungal agents. Med J Aust 2007,187(7),404-409","journal-title":"Med J Aust"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/978-1-4612-2762-5_6","volume":"4","author":"Ryder N.S.","year":"1992","unstructured":"Ryder N.S.; Mieth H.; Allylamine antifungal drugs. Curr Top Med Mycol 1992,4,158-188","journal-title":"Curr Top Med Mycol"},{"key":"ref=52","first-page":"603","volume":"15","author":"Allen U.","year":"2010","unstructured":"Allen U.; Antifungal agents for the treatment of systemic fungal infections in children. Paediatr Child Health 2010,15(9),603-615","journal-title":"Paediatr Child Health"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"119780","DOI":"10.1016\/j.ijpharm.2020.119780","volume":"589","author":"dos Santos R.M.A.","year":"2020","unstructured":"dos Santos R.M.A.; dos Santos K.C.; da Silva P.B.; Nanotechnological strategies for systemic microbial infections treatment: A review. Int J Pharm 2020,589,119780","journal-title":"Int J Pharm"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcis.2014.09.023","volume":"437","author":"Stiufiuc R.","year":"2015","unstructured":"Stiufiuc R.; Iacovita C.; Stiufiuc G.; Florea A.; Achim M.; Lucaciu C.M.; A new class of pegylated plasmonic liposomes: Synthesis and characterization. J Colloid Interface Sci 2015,437,17-23","journal-title":"J Colloid Interface Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijpharm.2017.04.013","volume":"525","author":"Fern&#xE1;ndez-Garc&#xED;a R.","year":"2017","unstructured":"Fern&#xE1;ndez-Garc&#xED;a R.; de Pablo E.; Ballesteros M.P.; Serrano D.R.; Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting. Int J Pharm 2017,525(1),139-148","journal-title":"Int J Pharm"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijpddr.2018.04.001","volume":"8","author":"Wijnant G.J.","year":"2018","unstructured":"Wijnant G.J.; Van Bocxlaer K.; Yardley V.; Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome&#xAE; and AmBisome&#xAE; in murine cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist 2018,8(2),223-228","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.apsb.2021.04.010","volume":"11","author":"Wang X.","year":"2021","unstructured":"Wang X.; Mohammad I.S.; Fan L.; Delivery strategies of amphotericin B for invasive fungal infections. Acta Pharm Sin B 2021,11(8),2585-2604","journal-title":"Acta Pharm Sin B"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1469-0691.2001.tb00012.x","volume":"7","author":"Tollemar J.","year":"2001","unstructured":"Tollemar J.; Klingspor L.; Ringd&#xE9;n O.; Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect 2001,7(S2),68-79","journal-title":"Clin Microbiol Infect"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijpharm.2010.07.003","volume":"397","author":"Sheikh S.","year":"2010","unstructured":"Sheikh S.; Ali S.M.; Ahmad M.U.; Nanosomal Amphotericin B is an efficacious alternative to Ambisome&#xAE; for fungal therapy. Int J Pharm 2010,397(1-2),103-108","journal-title":"Int J Pharm"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejps.2009.02.021","volume":"37","author":"Jung S.H.","year":"2009","unstructured":"Jung S.H.; Lim D.H.; Jung S.H.; Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci 2009,37(3-4),313-320","journal-title":"Eur J Pharm Sci"},{"key":"ref=61","first-page":"4733","volume":"8","author":"Burgess B.L.","year":"2013","unstructured":"Burgess B.L.; He Y.; Baker M.M.; NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Int J Nanomedicine 2013,8,4733-4743","journal-title":"Int J Nanomedicine"},{"key":"ref=62","first-page":"5403","volume":"9","author":"Tang X.","year":"2014","unstructured":"Tang X.; Zhu H.; Sun L.; Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo. Int J Nanomedicine 2014,9,5403-5413","journal-title":"Int J Nanomedicine"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jconrel.2012.05.037","volume":"161","author":"Van de Ven H.","year":"2012","unstructured":"Van de Ven H.; Paulussen C.; Feijens P.B.; PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome. J Control Release 2012,161(3),795-803","journal-title":"J Control Release"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s11671-015-0969-1","volume":"10","author":"Tang X.","year":"2015","unstructured":"Tang X.; Dai J.; Xie J.; Enhanced antifungal activity by Ab-modified amphotericin B-loaded nanoparticles using a pH-responsive block copolymer. Nanoscale Res Lett 2015,10(1),256","journal-title":"Nanoscale Res Lett"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/mp500527x","volume":"12","author":"Serrano D.R.","year":"2015","unstructured":"Serrano D.R.; Lalatsa A.; Dea-Ayuela M.A.; Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles. Mol Pharm 2015,12(2),420-431","journal-title":"Mol Pharm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2147\/IJN.S17503","volume":"6","author":"Xu N.","year":"2011","unstructured":"Xu N.; Julin G.; Yuanjie Z.; Hai W.; Qiushi R.; Jianghan C.; Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice. Int J Nanomedicine 2011,6,905-913","journal-title":"Int J Nanomedicine"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/IJN.S84656","volume":"10","author":"Tang X.","year":"2015","unstructured":"Tang X.; Zhu Y.; Dai J.; Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity. Int J Nanomedicine 2015,10,6227-6241","journal-title":"Int J Nanomedicine"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e0004754","DOI":"10.1371\/journal.pntd.0004754","volume":"10","author":"Saldanha C.A.","year":"2016","unstructured":"Saldanha C.A.; Garcia M.P.; Iocca D.C.; Antifungal activity of amphotericin B conjugated to nanosized magnetite in the treatment of paracoccidioidomycosis. PLoS Negl Trop Dis 2016,10(6),e0004754","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=69","first-page":"1769","volume":"10","author":"Zia Q.","year":"2015","unstructured":"Zia Q.; Khan A.A.; Swaleha Z.; Owais M.; Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Int J Nanomedicine 2015,10,1769-1790","journal-title":"Int J Nanomedicine"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijpharm.2005.05.027","volume":"301","author":"Pandey R.","year":"2005","unstructured":"Pandey R.; Ahmad Z.; Sharma S.; Khuller G.K.; Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery. Int J Pharm 2005,301(1-2),268-276","journal-title":"Int J Pharm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.colsurfb.2016.03.013","volume":"142","author":"Moazeni M.","year":"2016","unstructured":"Moazeni M.; Kelidari H.R.; Saeedi M.; Time to overcome fluconazole resistant Candida isolates: Solid lipid nanoparticles as a novel antifungal drug delivery system. Colloids Surf B Biointerfaces 2016,142,400-407","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.colsurfb.2018.12.011","volume":"175","author":"Domingues Bianchin M.","year":"2019","unstructured":"Domingues Bianchin M.; Borowicz S.M.; da Rosa Monte Machado G.; Lipid core nanoparticles as a broad strategy to reverse fluconazole resistance in multiple Candida species. Colloids Surf B Biointerfaces 2019,175,523-529","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/02652048.2012.714410","volume":"30","author":"Essa S.","year":"2013","unstructured":"Essa S.; Louhichi F.; Raymond M.; Hildgen P.; Improved antifungal activity of itraconazole-loaded PEG\/PLA nanoparticles. J Microencapsul 2013,30(3),205-217","journal-title":"J Microencapsul"},{"key":"ref=74","first-page":"1415","volume":"10","author":"Qiu L.","year":"2015","unstructured":"Qiu L.; Hu B.; Chen H.; Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles. Int J Nanomedicine 2015,10,1415-1423","journal-title":"Int J Nanomedicine"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jddst.2018.02.014","volume":"45","author":"Cunha-Azevedo E.P.","year":"2018","unstructured":"Cunha-Azevedo E.P.; Py-Daniel K.R.; Siqueira-Moura M.P.; In vivo evaluation of the efficacy, toxicity and biodistribution of PLGA-DMSA nanoparticles loaded with itraconazole for treatment of paracoccidioidomycosis. J Drug Deliv Sci Technol 2018,45,135-141","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.nano.2012.04.005","volume":"9","author":"Sinha B.","year":"2013","unstructured":"Sinha B.; Mukherjee B.; Pattnaik G.; Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine 2013,9(1),94-104","journal-title":"Nanomedicine"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijpharm.2007.10.009","volume":"352","author":"Peng H.","year":"2008","unstructured":"Peng H.; Liu X.; Lv G.; Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy. Int J Pharm 2008,352(1-2),29-35","journal-title":"Int J Pharm"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/10717544.2018.1492046","volume":"25","author":"Veloso D.F.M.C.","year":"2018","unstructured":"Veloso D.F.M.C.; Benedetti N.I.G.M.; &#xC1;vila R.I.; Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity. Drug Deliv 2018,25(1),1585-1594","journal-title":"Drug Deliv"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrd3074","volume":"9","author":"Ostrosky-Zeichner L.","year":"2010","unstructured":"Ostrosky-Zeichner L.; Casadevall A.; Galgiani J.N.; Odds F.C.; Rex J.H.; An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010,9(9),719-727","journal-title":"Nat Rev Drug Discov"},{"key":"ref=80","first-page":"11","volume":"2015","author":"Aguirre J.P.","year":"2015","unstructured":"Aguirre J.P.; Hamid A.M.; Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev 2015,2015,11","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","volume":"49","author":"Dupont B.","year":"2002","unstructured":"Dupont B.; Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002,49(S1),31-36","journal-title":"J Antimicrob Chemother"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/jac\/dkl005","volume":"57","author":"Takemoto K.","year":"2006","unstructured":"Takemoto K.; Yamamoto Y.; Ueda Y.; Sumita Y.; Yoshida K.; Niki Y.; Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 2006,57(4),724-731","journal-title":"J Antimicrob Chemother"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","volume":"50","author":"Andes D.","year":"2006","unstructured":"Andes D.; Safdar N.; Marchillo K.; Conklin R.; Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006,50(2),674-684","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.nano.2016.07.006","volume":"12","author":"Niemirowicz K","year":"2016","unstructured":"Niemirowicz K; Durna&#x15B; B, Tokajuk G, et al. Magnetic nanoparticles as a drug delivery system that enhance fungicidal activity of polyene antibiotics. Nanomedicine 2016,12(8),2395-2404","journal-title":"Nanomedicine"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11095-016-2062-6","volume":"34","author":"Mohammadi G.","year":"2017","unstructured":"Mohammadi G.; Shakeri A.; Fattahi A.; Preparation, physicochemical characterization and anti-fungal evaluation of nystatin-loaded PLGA-glucosamine nanoparticles. Pharm Res 2017,34(2),301-309","journal-title":"Pharm Res"},{"key":"ref=86a","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/AAC.41.3.575","volume":"Mar 41","author":"Ruhnke M.","year":"1997","unstructured":"Ruhnke M.; Schmidt-Westhausen A.; Trautmann M.; In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997,Mar 41(3),575-577","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=86b","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.molpharmaceut.5b00064","volume":"12","author":"Das P.J.","year":"2015","unstructured":"Das P.J.; Paul P.; Mukherjee B.; Mazumder B, Mondal L, Baishya R, Debnath MC, Dey KS Pulmonary delivery of voriconazole loaded nanoparticles providing a prolonged drug level in lungs: a promise for treating fungal infection. Mol Pharm 2015,12(8),2651-2664","journal-title":"Mol Pharm"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12281-014-0185-y","volume":"8","author":"Percival K.M.","year":"2014","unstructured":"Percival K.M.; Bergman S.J.; Update on posaconazole pharmacokinetics: comparison of old and new formulations. Curr Fungal Infect Rep 2014,8(2),139-145","journal-title":"Curr Fungal Infect Rep"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","volume":"30","author":"Brunet K.","year":"2020","unstructured":"Brunet K.; Rammaert B.; Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Med 2020,30(3),101007","journal-title":"J Mycol Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"106291","DOI":"10.1016\/j.ijantimicag.2021.106291","volume":"57","author":"Beredaki M.I.","year":"2021","unstructured":"Beredaki M.I.; Arendrup M.C.; Mouton J.W.; Meletiadis J.; In-vitro pharmacokinetic\/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. Int J Antimicrob Agents 2021,57(3),106291","journal-title":"Int J Antimicrob Agents"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fcimb.2020.00469","volume":"10","author":"Ademe M.","year":"2020","unstructured":"Ademe M.; Immunomodulation for the treatment of fungal infections: opportunities and challenges. Front Cell Infect Microbiol 2020,10,469","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"110550","DOI":"10.1016\/j.biopha.2020.110550","volume":"130","author":"Pathakumari B.","year":"2020","unstructured":"Pathakumari B.; Liang G.; Liu W.; Immune defence to invasive fungal infections: A comprehensive review. Biomed Pharmacother 2020,130,110550","journal-title":"Biomed Pharmacother"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S1473-3099(17)30442-5","volume":"17","author":"Armstrong-James D.","year":"2017","unstructured":"Armstrong-James D.; Brown G.D.; Netea M.G.; Immunotherapeutic approaches to treatment of fungal diseases. Lancet Infect Dis 2017,17(12),e393-e402","journal-title":"Lancet Infect Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cyto.2008.03.002","volume":"42","author":"Panopoulos A.D.","year":"2008","unstructured":"Panopoulos A.D.; Watowich S.S.; Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and \u2018emergency\u2019 hematopoiesis. Cytokine 2008,42(3),277-288","journal-title":"Cytokine"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/infdis\/jit574","volume":"209","author":"Voigt J.","year":"2014","unstructured":"Voigt J.; H&#xFC;nniger K.; Bouzani M.; Human natural killer cells acting as phagocytes against Candida albicans and mounting an inflammatory response that modulates neutrophil antifungal activity. J Infect Dis 2014,209(4),616-626","journal-title":"J Infect Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.biopha.2018.10.075","volume":"109","author":"Nami S.","year":"2019","unstructured":"Nami S.; Mohammadi R.; Vakili M.; Khezripour K.; Mirzaei H.; Morovati H.; Fungal vaccines, mechanism of actions and immunology: A comprehensive review. Biomed Pharmacother 2019,109,333-344","journal-title":"Biomed Pharmacother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1201-9712(02)90104-9","volume":"6","author":"Roilides E.","year":"2002","unstructured":"Roilides E.; Gil Lamaignere C.; Farmaki E.; Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int J Infect Dis 2002,6(3),154-163","journal-title":"Int J Infect Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1590\/0074-02760150335","volume":"110","author":"Medici N.P.","year":"2015","unstructured":"Medici N.P.; Del Poeta M.; New insights on the development of fungal vaccines: from immunity to recent challenges. Mem Inst Oswaldo Cruz 2015,110(8),966-973","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/phar.1652","volume":"35","author":"Rybak J.M.","year":"2015","unstructured":"Rybak J.M.; Marx K.R.; Nishimoto A.T.; Rogers P.D.; Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. Pharmacotherapy 2015,35(11),1037-1051","journal-title":"Pharmacotherapy"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","volume":"14","author":"Sofjan A.K.","year":"2018","unstructured":"Sofjan A.K.; Mitchell A.; Shah D.N.; Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist 2018,14,58-64","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1590\/S0074-02762011000200022","volume":"106","author":"Sesana A.M.","year":"2011","unstructured":"Sesana A.M.; Monti-Rocha R.; Vinhas S.A.; Morais C.G.; Dietze R.; Lemos E.M.; In vitro activity of amphotericin B cochleates against Leishmania chagasi. Mem Inst Oswaldo Cruz 2011,106(2),251-253","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/jof6030122","volume":"6","author":"Wiederhold N.P.","year":"2020","unstructured":"Wiederhold N.P.; Review of the novel investigational antifungal olorofim. J Fungi 2020,6(3),122","journal-title":"J Fungi"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd.2017.46","volume":"16","author":"Perfect J.R.","year":"2017","unstructured":"Perfect J.R.; The antifungal pipeline: a reality check. Nat Rev Drug Discov 2017,16(9),603-616","journal-title":"Nat Rev Drug Discov"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","volume":"73","author":"Brand S.R.","year":"2021","unstructured":"Brand S.R.; Sobel J.D.; Nyirjesy P.; Ghannoum M.A.; Schotzinger R.J.; Degenhardt T.P.; A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal Candidiasis. Clin Infect Dis 2021,73(7),e1518-e1524","journal-title":"Clin Infect Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1128\/AAC.05954-11","volume":"56","author":"Shibata T.","year":"2012","unstructured":"Shibata T.; Takahashi T.; Yamada E.; T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother 2012,56(11),5892-5897","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/jac\/dkv398","volume":"71","author":"Wiederhold N.P.","year":"2016","unstructured":"Wiederhold N.P.; Najvar L.K.; Fothergill A.W.; The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata. J Antimicrob Chemother 2016,71(3),692-695","journal-title":"J Antimicrob Chemother"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"670731","DOI":"10.3389\/fmed.2021.670731","volume":"8","author":"Samaddar A.","year":"2021","unstructured":"Samaddar A.; Sharma A.; Emergomycosis, an emerging systemic mycosis in immunocompromised patients: current trends and future prospects. Front Med 2021,8,670731","journal-title":"Front Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1128\/AAC.00349-16","volume":"60","author":"Warrilow A.G.S.","year":"2016","unstructured":"Warrilow A.G.S.; Parker J.E.; Price C.L.; The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob Agents Chemother 2016,60(8),4530-4538","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666221128122836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211303\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666221128122836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T04:42:16Z","timestamp":1680151336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211303\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450124666221128122836","relation":{},"ISSN":["1389-4501"],"issn-type":[{"type":"print","value":"1389-4501"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}